GSTM3 and cancer: Gene superfamily of glutathione S-transferase (GST), including GSTM3, as a phase II xenobiotic and drug detoxification enzyme (Deponte, 2013[14]; Di Pietro et al., 2010[16]; Hollman et al., 2016[28]; Sturchio et al., 2008[61]; Tóth et al., 2015[65]; Xie et al., 2015[76]), acts in conjugation with phase I enzymes such as CYPs (Vaish et al., 2020[67]), and this superfamily is also considered critical enzymes in drug resistance, especially in cancers (Singh and Reindl, 2021[58]).